Post-earnings recap
Reported
Wed, Mar 7, 2018
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
25%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Viking Therapeutics reported a loss of $0.14 per share, but did not disclose revenue figures. The stock fell by 0.99% following the earnings report, reflecting investor uncertainty. The lack of guidance and focus on clinical trials suggests that the company is prioritizing long-term development over short-term financial performance.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.14 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
Management emphasized the importance of ongoing clinical trials. They did not provide specific guidance, indicating a cautious approach to future projections.
Management did not provide specific revenue guidance for the upcoming quarters.
The focus remains on advancing clinical trials and product development.